Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in B-precursor ALL with MRD
NCT03109093Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Mar 2017
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoint: Minimal Residual Disease response after one cycle at 43 days. Started Mar 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03109093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109093.